Clinical Trial

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
Protocol Amendment History 4 changes
critical Trial completed 2026-05-23
notable Enrollment increased: 16 -> 22 participants 2026-05-23
notable Primary completion moved earlier: 2026-12 -> 2026-04-30 2026-05-23
minor Completion moved earlier: 2027-02 -> 2026-04-30 2026-05-23
Trial Details
NCT Number NCT07340216
Lead Sponsor Arcutis Biotherapeutics, Inc.
Conditions Psoriasis
Enrollment 22 participants
Start Date 2025-12-15
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22